Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.

@article{Diener2007CessationVC,
  title={Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.},
  author={Hans-Christoph Diener and Reto M. Agosti and Gianni Allais and P. L. M. Bergmans and Gennaro Bussone and Brendan Davies and Mustafa Ertas and Michel Lant{\'e}ri-Minet and Uwe Reuter and Margarita S{\'a}nchez del R{\'i}o and Jean Schoenen and Susanne Schwalen and Joop C van Oene},
  journal={The Lancet. Neurology},
  year={2007},
  volume={6 12},
  pages={1054-62}
}
BACKGROUND Use of preventive therapy for migraine is often recommended for only 6-9 months, but no randomised, placebo-controlled trials have investigated migraine frequency after the end of prophylaxis. We assessed the effects of discontinuation of topiramate after a treatment period of 6 months. METHODS 818 patients who have migraines were enrolled from 88 clinics in 21 countries. After a 4-8-week lead-in period, patients received topiramate in a 26-week open-label phase. Daily dose was… CONTINUE READING

From This Paper

Topics from this paper.
40 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Similar Papers

Loading similar papers…